Procaps Group, S.A Price to Free Cash Flow Ratio 2020-2023 | PROCF

Procaps Group, S.A price to free cash flow ratio from 2020 to 2023. Price to free cash flow ratio can be defined as

Procaps Group, S.A Price to Free Cash Flow Ratio 2020-2023 | PROCF

Procaps Group, S.A price to free cash flow ratio from 2020 to 2023. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$81.3B
Zoetis (ZTS)$67.2B
Daiichi Sankyo, - (DSNKY)$46.3B
Takeda Pharmaceutical (TAK)$45.6B
BeOne Medicines - (ONC)$33.5B
Sandoz Group AG (SDZNY)$26B
Summit Therapeutics (SMMT)$19.9B
Merck (MKKGY)$16.9B
Shionogi (SGIOY)$14.3B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.3B
Orion OYJ (ORINY)$11.4B
IPSEN (IPSEY)$10.8B
Stevanato Group S.p.A (STVN)$7.7B
Corcept Therapeutics (CORT)$7.2B
Grifols, S.A (GRFS)$7.2B
Ionis Pharmaceuticals (IONS)$6.6B
Madrigal Pharmaceuticals (MDGL)$6.5B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.2B
Hypermarcas (HYPMY)$3B
Crinetics Pharmaceuticals (CRNX)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
ARS Pharmaceuticals (SPRY)$1.7B